振东制药
(300158)
| 流通市值：46.09亿 | | | 总市值：46.24亿 |
| 流通股本：10.24亿 | | | 总股本：10.27亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 782,130,269.05 | 3,626,016,132.88 | 2,783,745,444.64 | 1,932,888,842.05 |
| 营业收入 | 782,130,269.05 | 3,626,016,132.88 | 2,783,745,444.64 | 1,932,888,842.05 |
| 二、营业总成本 | 795,147,632.83 | 3,777,432,266.55 | 2,795,510,880.16 | 1,921,339,890.75 |
| 营业成本 | 434,918,773.98 | 1,799,416,384.46 | 1,369,609,399.07 | 982,899,322.05 |
| 税金及附加 | 8,368,750.49 | 34,828,933.47 | 25,341,313.03 | 18,204,705.4 |
| 销售费用 | 265,263,924.42 | 1,475,860,575.64 | 1,072,756,701.01 | 715,645,260.43 |
| 管理费用 | 48,597,410.7 | 285,877,010.06 | 198,355,911.4 | 122,550,337.59 |
| 研发费用 | 38,447,733.67 | 191,015,445.76 | 137,283,367.79 | 88,740,206.71 |
| 财务费用 | -448,960.43 | -9,566,082.84 | -7,835,812.14 | -6,699,941.43 |
| 其中:利息费用 | 295,179.14 | 1,200,933 | 998,651.59 | 941,615.42 |
| 其中:利息收入 | 1,010,550.68 | 11,591,513.78 | 9,983,177.65 | 7,911,421.34 |
| 加:公允价值变动收益 | 2,649,261.36 | 1,957,834.93 | 3,634,684.17 | 4,663,843.67 |
| 加:投资收益 | 16,888,805.04 | 43,081,643.45 | 23,736,148.67 | 16,934,567.39 |
| 资产处置收益 | 10,207,738.19 | 291,960.96 | 192,609.6 | 170,147.6 |
| 资产减值损失(新) | 1,630,943.08 | -36,242,490.16 | -15,770,230.63 | -10,858,154.25 |
| 信用减值损失(新) | -604,975.44 | 17,448,995.7 | -21,635,427.84 | -22,035,634.53 |
| 其他收益 | 14,535,258.03 | 94,894,744.67 | 33,345,000.05 | 28,158,427.79 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 32,289,666.48 | -29,983,444.12 | 11,737,348.5 | 28,582,148.97 |
| 加:营业外收入 | 310,896.87 | 1,980,368.61 | 2,071,303.72 | 1,647,408.38 |
| 减:营业外支出 | 1,607,370.25 | 9,689,582.45 | 2,651,262.92 | 739,515.24 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 30,993,193.1 | -37,692,657.96 | 11,157,389.3 | 29,490,042.11 |
| 减:所得税费用 | 8,646,068.74 | 10,176,544.56 | 15,291,462.89 | 17,280,721.86 |
| 六、净利润 | 22,347,124.36 | -47,869,202.52 | -4,134,073.59 | 12,209,320.25 |
| 持续经营净利润 | 22,347,124.36 | -47,869,202.52 | -4,134,073.59 | 12,209,320.25 |
| 归属于母公司股东的净利润 | 23,101,557.95 | -43,984,116.23 | -874,204.92 | 14,542,410.37 |
| 少数股东损益 | -754,433.59 | -3,885,086.29 | -3,259,868.67 | -2,333,090.12 |
| (一)基本每股收益 | 0.02 | -0.04 | 0 | 0.01 |
| (二)稀释每股收益 | 0.02 | -0.04 | 0 | 0.01 |
| 八、其他综合收益 | -4.44 | -31,313,124.34 | -31,342,821.29 | -31,335,731.08 |
| 归属于母公司股东的其他综合收益 | -4.44 | -31,313,124.34 | -31,342,821.29 | -31,335,731.08 |
| 九、综合收益总额 | 22,347,119.92 | -79,182,326.86 | -35,476,894.88 | -19,126,410.83 |
| 归属于母公司股东的综合收益总额 | 23,101,553.51 | -75,297,240.57 | -32,217,026.21 | -16,793,320.71 |
| 归属于少数股东的综合收益总额 | -754,433.59 | -3,885,086.29 | -3,259,868.67 | -2,333,090.12 |
| 公告日期 | 2024-04-23 | 2024-04-23 | 2023-10-23 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |